Among growth hormone-releasing peptides, no combination comes up in the research literature more often than the CJC-1295 ipamorelin stack. Individually, each compound targets a different part of the GH-release pathway. Together, they’re studied as a complementary pair, which is exactly why so many researchers purchase them as a stack rather than in isolation. This guide covers how each compound works, why they’re paired, and what to know when sourcing them for research.
Two Different Mechanisms, One Pathway
Growth hormone release from the pituitary gland is regulated by two separate signaling systems, and the CJC-1295 ipamorelin stack targets both of them at once. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary and stimulates the synthesis and release of growth hormone. Many research-grade formulations include a modification called DAC (Drug Affinity Complex), which binds to albumin and extends the peptide’s half-life significantly compared to unmodified GHRH.
Ipamorelin: A Selective GHRP
Ipamorelin is a growth hormone-releasing peptide (GHRP) and ghrelin receptor agonist. It stimulates GH release through a separate mechanism, mimicking ghrelin’s action at the GH secretagogue receptor. What distinguishes Ipamorelin from older GHRPs like GHRP-6 or GHRP-2 is its selectivity: research indicates it stimulates GH release with minimal impact on cortisol, prolactin, or acetylcholine levels, commonly-reported side effects of less-selective secretagogues in animal and in-vitro models.
Why the CJC-1295 Ipamorelin Stack Is Studied Together
Because CJC-1295 and Ipamorelin act on two distinct receptor systems, the GHRH receptor and the ghrelin/GHS receptor, their effects on GH release are considered synergistic rather than additive in research models studying combined GHRH/GHRP administration. Activating both pathways simultaneously produces a stronger pulsatile GH release than either compound alone at comparable doses. This dual-mechanism approach mirrors a broader pattern seen elsewhere in peptide research, much like how dual and triple incretin agonists such as tirzepatide peptide combine multiple receptor pathways for a compounded effect.
What Research Has Shown About Each Pathway
GHRH pathway activation from CJC-1295 is associated in research models with increased amplitude of natural GH pulses without disrupting the body’s normal pulsatile secretion pattern. Ghrelin receptor activation from Ipamorelin is associated with GH release that closely mimics the body’s natural secretory pattern, with a favorable selectivity profile relative to first-generation GHRPs. Combined administration in research settings has been used to study downstream effects on IGF-1 levels, body composition markers, and sleep-related GH secretion patterns in model systems.
Sourcing a CJC-1295 Ipamorelin Stack for Research
Because this is a two-compound protocol, consistency and documentation across both peptides matters. Confirm whether CJC-1295 includes DAC or not, since this materially changes its half-life and is a critical variable in any comparative research design. Request batch-specific Certificates of Analysis for both compounds, verified via HPLC/mass spectrometry. We carry research-grade CJC-1295 without DAC + Ipamorelin, individually as CJC-1295 with DAC and Ipamorelin, or as a documented pair, alongside our full range of research peptides.
CJC-1295 Ipamorelin Stack: Related Research Compounds
Researchers studying GH-axis peptides alongside other metabolic research compounds often compare the CJC-1295 ipamorelin stack against fat-metabolism-specific peptides like AOD9604 and the NNMT inhibitor 5-Amino-1MQ, or against incretin-pathway compounds like retatrutide. Reviewing each mechanism helps put the GHRH/ghrelin dual-pathway activity of this stack in context.
Frequently Asked Questions
Why combine CJC-1295 and Ipamorelin instead of using one alone? Because they act on two distinct receptor systems, research models show their combined effect on GH release is synergistic rather than additive compared to either compound alone.
What’s the difference between CJC-1295 with and without DAC? DAC extends the peptide’s half-life from minutes to potentially several days by binding to albumin, while non-DAC formulations are studied for a more pulsatile release pattern.
Is the CJC-1295 ipamorelin stack approved for human use? No. Both compounds are sold strictly for laboratory research and are not approved for human administration.
Final Thoughts
The CJC-1295 ipamorelin stack remains one of the most studied GH-secretagogue combinations because it pairs two genuinely distinct receptor mechanisms rather than duplicating one pathway. That dual-mechanism design, and the ability to cross-reference both compounds’ documented research history, is what continues to drive interest in studying them together.